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Absence of PRKAR1A Loss of Heterozygosity in Laser-Captured 
Microdissected Pigmented Nodular Adrenocortical 
Tissue from a Patient with Carney Complex Caused 
by the Novel Nonsense Mutation p.Y21X
ABSTRACT
Objective: Primary pigmented nodular adrenocortical disease (PPNAD) is the 
main endocrine manifestation of Carney complex, a multiple neoplasia syn-
drome caused by PRKAR1A gene mutations. The presence of PRKAR1A loss 
of heterozygosity (LOH) in adrenocortical tumorigenesis remains controver-
sial. The aim of the present study is to investigate the presence of PRKAR1A 
LOH in adrenocortical cells in a patient with Carney complex. Methods: The 
LOH was investigated using a PRKAR1A informative intragenic marker by Ge-
neScan software analysis in DNA obtained from laser-captured microdissect-
ed cells of several adrenal nodules. Patients: A young adult male patient with 
Carney complex and his family were studied. Results: A novel heterozygous 
mutation (p. Y21X) was identifi ed at PRKAR1A in blood DNA of the male 
proband and his relatives. No PRKAR1A LOH was evidenced in the laser-cap-
tured microdissected cells from PPNAD tissue by different methodologies. 
Conclusion: We identifi ed a new PRKAR1A nonsense mutation and in addi-
tion we did not evidence PRKAR1A LOH in laser-captured nodules cells, sug-
gesting that adrenocortical tumorigenesis in PPNAD may occurs apart from 
the second hit. (Arq Bras Endocrinol Metab 2008; 52/8:1257-1263)
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RESUMO
Ausência da Perda de Heterozigose do PRKAR1A em Células Capturadas por 
Microdissecção a Laser de Tecido de Nódulo Pigmentoso Adrenocortical de 
um Paciente com Complexo de Carney Causado por uma Nova Mutação 
Nonsense.
Objetivo: A doença adrenocortical nodular pigmentosa primária (PPNAD) é 
uma das manifestações do complexo de Carney, uma neoplasia endócrina 
múltipla causada por mutações no PRKAR1A. A perda de heterozigose (LOH) 
do PRKAR1A na tumorigenese adrenal permanece controversa dada à pos-
sibilidade de contaminação com o tecido normal. Nosso objetivo foi investi-
gar a presença de LOH no PRKAR1A a partir de células do nódulo adrenal de 
um paciente com complexo de Carney. Métodos: A pesquisa da LOH do 
PRKAR1A foi realizada através do estudo de um marcador intragênico em 
DNA de células do nódulo adrenal microdissecadas a laser, evitando con-
taminação com o tecido normal. Pacientes: Um paciente com PPNAD e cinco 
familiares foram estudados. Resultados: A nova mutação (p. Y21X) foi identi-
fi cada no PRKAR1A sem evidência de LOH no tecido adrenal. Conclusão: 
Identifi camos uma nova mutação no PRKAR1A e não evidenciamos LOH nas 
células dos nódulos adrenocorticais, sugerindo que a PPNAD possa ocorrer 
na ausência de um segundo evento molecular. (Arq Bras Endocrinol Metab 
2008; 52/8:1257-1263)
Descritores: PRKAR1A; PPNAD; LOH; Microdissecção; Captura a laser
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ture (13,14). Very recently, Mavrakis and cols. (15) 
demonstrated the presence of LOH exclusively in 
nodular areas of laser-captured microdissected PP-
NAD tissue from a patient with Carney complex. 
However, PRKAR1A LOH was based only on the 
segregation of a single polymorphic marker (GA-
TA1E12) located 3 cM upstream the PRKAR1A 
gene, which makes this fi nding very inconsistent (15). 
Therefore, additional LOH studies in laser-captured 
microdissected adrenal nodules of PPNAD tissue 
would be relevant to clarify the controversial aspects 
involving PRKAR1A LOH occurrence. Herein, we 
carried out an LOH analysis for an intragenic PRKA-
R1A marker in laser-captured microdissected cells of 
PPNAD tissue from a patient with familial Carney 
complex, caused by a novel PRKAR1A mutation.
SUBJECTS AND METHODS
The protocol was approved by the Ethical Committee 
of Hospital das Clinicas, School of Medicine of the 
University of São Paulo. Informed and written consent 
was obtained from the proband and his relatives. 
A 17-year-old male patient was referred for endo-
crine evaluation of suspected Cushing’s syndrome. He 
presented central obesity (BMI 32 kg/m2), facial ple-
thora, abdominal purple striae, spotty skin pigmenta-
tion (lentiginoses) and high blood pressure (160/100 
mmHg). Hormonal investigation revealed ACTH-in-
dependent Cushing syndrome (Table 1). Magnetic re-
sonance imaging (MRI) revealed multiple left and right 
adrenocortical micronodules (Figure 1A). Testicular, 
INTRODUCTION
Carney complex is a multiple endocrine neoplasia syndrome characterized by spotty skin pigmenta-
tion, cardiac and extracardiac myxomas, schwannomas, 
and endocrine tumours (1). Primary pigmented nodular 
adrenocortical disease (PPNAD), a rare cause of ACTH-
independent Cushing syndrome, is the main endocrine 
manifestation of Carney complex (1,2). Mutations of 
the gene encoding protein kinase A regulatory subunit 
1α (PRKAR1A) represent the molecular aetiology of 
approximately 41% of the kindreds affected by Carney 
complex (3-6). Additionally, genetic linkage analysis has 
identifi ed other genetic loci on chromosome 2p in fami-
lies with Carney complex (7,8).
PRKAR1A appears to function as a classic tumour 
suppressor gene(3). To date, PRKAR1A loss of het-
erozygosity (LOH) studies were reported in 16 le-
sions caused by Carney complex (3,4,9-12). In several 
of these cases, tumours displayed 17q22-24 LOH or 
allelic loss, particularly in GH-producing pituitary ad-
enomas, thyroid and testicular tumours (3,10). In 
contrast, subsequent studies demonstrated that cardi-
ac and other myxomas exhibited PRKAR1A LOH 
inconsistently (4,9). In addition, retention of hetero-
zygosity was also demonstrated by direct sequencing 
of PRKAR1A in adrenocortical tissue from three pa-
tients with isolated PPNAD (11). LOH analysis can 
often be misdiagnosing due to signifi cant contamina-
tion with normal cells that surround tumours. The 
laser-captured microdissection is currently considered 
the best way to overcome surrounding tissue admix-
Table 1. Clinical, hormonal, and imaging fi ndings of a family with Carney complex caused by the p. Y21X mutation of the 
PRKAR1A.
Proband Father Sister 1 Sister 2
Age at the initial evaluation (yr) 17 52 15 13
Lentiginoses Yes Yes Yes Yes
Overt Cushing syndrome Yes No No No
8 am serum cortisol*
(normal levels < 1.8 µg/dL)
29 2.0 5.1 4.6
ACTH (normal levels: 18-60 pg/mL) < 18 < 18 < 18 < 18
24-h urinary non-extracted cortisol 
(normal levels < 300 µg/24 h)
1736 345 258 215
Adrenal CT scan micronodules normal normal normal
Low bone mass Yes NA¶ NA¶ Yes
*Plasma cortisol after low-dose (1 mg) dexamethasone suppression test; ¶NA, not available; Cortisol conversion: metric unit (µg/dL) x 27.59= SI (nmol/L); ACTH 
conversion: metric unit (pg/mL) ÷ 103= SI (µg/L).
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thyroid and cardiac ultrasound and pituitary MRI were 
normal. Serum concentrations of GH, prolactin and 
IGFI were within the normal range.
He underwent laparoscopic bilateral adrenalec-
tomy. Both adrenal glands had an overall normal size 
and weight and featured multiple small yellow to dark 
brown nodules. Microscopically, both adrenal glands 
showed several multiple pigmented nodules (1-5 mm) 
surrounded by apparently normal adjacent adrenal cor-
tex; Fontana-Masson staining revealed intracellular li-
pofuscin pigments (Figure 1B).
Four fi rst-degree relatives were evaluated through 
history and physical examination. Hormonal and imaging 
screenings for diagnosis of hypercortisolism were perfor-
med in his father and two younger sisters without 
Cushing’s syndrome features. Bone densitometry was also 
performed in the male proband and his youngest sister.
Hormonal assays
ACTH was measured by an immunoradiometric kit 
(ELSA-ACTH, CIS bio international) with intra- and 
interassay CVs <14% and <20%, respectively, which are 
appropriate for an ACTH range of 18-2,420 pg/mL. 
Serum and urinary cortisol were measured by fl uoroim-
munoassay in an AutoDelfi a System (Wallac Oy, Turku, 
Finland), with intra- and interassay coeffi cients of varia-
tion (CVs) <10% and <12%, respectively.
DNA analysis
Genomic DNA was extracted from peripheral blood 
leukocytes and frozen tumour tissue of the proband 
using standard procedures. Molecular studies were also 
performed in six relatives (his parents, two sisters, one 
paternal aunt and a female cousin). The 12 exons and 
the fl anking intronic sequences of the PRKAR1A gene 
Figure 1. (A) Adrenal MRI revealed small bilateral adrenal nodules (arrows). (B) Intracellular lipofuscin pigments revealed by 
Fontana-Masson staining. (C) Pedigree of the family with Carney complex. *Short stature and a past history of precocious pu-
berty, but without hormonal investigation. (D) Nonsense PRKAR1A mutation in exon 2 at codon 21 (TAC→TAA) encoding a 
substitution of a tyrosine by a stop codon (p. Y21X).
A B
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were amplifi ed using the previously described primers 
and conditions (5). The PCR products were pretreated 
with an enzymatic combination of exonuclease I and 
shrimp alkaline phosphatase (United 7 States Bioche-
mical Corp., Cleveland, OH) and directly sequenced 
using the BigDyeTM terminator cycle sequencing rea-
dy reaction kit (PE Applied Biosystems, Foster City, 
CA) in an ABI PRISM 310 automatic sequencer (Perkin 
Elmer Cetus).
Laser-captured microdissection and DNA 
extraction of PPNAD cells
Adrenal frozen tissue was cut into 7-μm sections and 
subsequently hydrated in 70% ethanol solution for 
30 seconds, followed by staining with 100 μl of To-
luidine blue for 20 seconds after rinsing with distil-
led water. The sections were dehydrated in graded 
75%, 95% and 100% ethanol for 30 seconds each and 
dipped in xylene for 5 minutes. After air-drying, la-
ser-captured microdissection was performed in selec-
ted regions onto a thermoplastic fi lm mounted on 
optically transparent LCM cap (CapSure Macro 
LCM Cap, Arcturus). A Pix Cell II Laser capture ins-
trument (Arcturus, Mountain View, CA) was used to 
microdissect several PPNAD nodules (>10,000 cells) 
by focal melting of the membrane through laser acti-
vation. A cap with captured cells was inserted into a 
0.5 ml microcentrifuge tube and DNA extraction 
was performed according to Pico pure DNA Extrac-
tion Kit (Arcturus, Mountain View, CA). The exon 2 
of PRKAR1A was amplifi ed and sequenced as pre-
viously described (5).
PRKAR1A LOH analysis
Primer for the dinucleotide repeats (CA)n intragenic 
marker for PRKAR1A gene have been published el-
sewhere (5). The forward primer was labelled with fl u-
orescent dye (FAM). Genomic DNA (100 ng), 
extracted from blood leukocytes, PPNAD tissue and 
laser-captured microdissected tumour cells was then 
added to a 50-µl reaction mixture of 1x PCR buffer 
(50 mM KCl, 1.5 mM MgCl2, and 10 mM Tris/HCl, 
pH 9.0), 200 µM of each dNTP, 20 pmol of each pri-
mer, and 2.5 U Taq DNA polymerase (Amersham 
Pharmacia, Uppsala, Sweden). The PCR mixture was 
denatured for 5 min at 94 °C and cycled 35 times (94 
°C for 30 sec, 50–62 °C for 30 sec, and 72 °C for 30 
sec), followed by a 30-min extension at 72 °C. Inter-
nal size standard TAMRA 350 (Applied Biosystems, 
Foster City, CA) was added to 2 µl of PCR products and 
24 µl of formamide, and those were submitted to capilla-
ry electrophoresis in an automatic sequencer (ABI Prism 
310 genetic analyser) followed by GeneScan fragment 
analysis (Applied Biosystems, Foster City, CA). We ap-
plied a criterion for LOH scoring using the ratio of the 
heights of the allele peaks obtained from the tumour and 
the blood samples. An allelic imbalance ratio less than 
0.5 or more than 2.0 was defi ned as LOH (16,17).
RESULTS
Automated sequencing revealed a novel germline 
PRKAR1A mutation in exon 2 at codon 21 
(TAC→TAA), encoding a substitution of a tyrosine by 
a stop codon (p. Y21X), in heterozygous state in the 
proband as well as in his father, two younger sisters, 
one paternal aunt and a female cousin (Figure 1C and 
1D). All of them exhibited lentiginoses. Even though 
only the proband had overt Cushing syndrome, his fa-
ther and the two sisters who carried the same mutation 
had evidence of hormonal abnormalities (Table 1) (18). 
Although the serum cortisol levels after overnight 1 mg 
dexamethasone test were borderline, the suppressed 
ACTH levels, as well as the slightly elevated 24-h uri-
nary non-extracted cortisol indicated the diagnosis of 
subclinical cortisol hypersecretion in the father. Simi-
larly, both sisters also had suppressed ACTH levels and 
non-suppressed serum cortisol levels after the overni-
ght low-dose dexamethasone suppression test. The 
male proband and his youngest sister also presented 
low bone mass (Z score < -2 SD).
The p. Y21X mutation was also identifi ed in hete-
rozygous state in PPNAD tissue from the proband. 
The sequencing analysis of the entire coding region of 
the PRKAR1A ruled out the possibility of a somatic 
defect in compound heterozygosity with the p. Y21X 
mutation in this patient. Two distinct alleles of the in-
tragenic marker for PRKAR1A were identifi ed in DNA 
from blood lymphocytes as well as in adrenocortical tu-
mour tissue, demonstrating no allelic loss involving 
PRKAR1A gene in PPNAD tissue. Absence of PRKA-
R1A LOH for the p. Y21X mutation as well as for the 
dinucleotide repeat (CA)n intragenic marker were con-
fi rmed in DNA obtained from PPNAD cells after laser-
captured microdissection, indicating that wild-type 
(WT) PRKAR1A allele retention is not a consequence 
of normal tissue contamination (Figure 2).
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DISCUSSION
Tumour-suppressor genes generally act in a recessive 
way, requiring loss of both copies to induce tumorige-
nesis, whereas haploinsuffi ciency only leads to tumour 
development predisposition. However, PRKAR1A, a 
potential tumour suppressor gene, has not been consis-
tently associated with LOH in adrenocortical tumour 
tissues of patients with Carney complex. This might be 
ascribed to the fact that the exclusion of potential nor-
mal tissue contamination was not performed (4,12).
A recent LOH study using a single polymorphic 
marker GATA1E12, located 3 cM upstream the PRKA-
R1A gene, showed LOH occurrence only in microdis-
sected PPNAD tissue, suggesting that the absence of 
LOH in previous analyses could occur due to contami-
nation with surrounding cortex (15). In our study, 
both the p. Y21X mutation and the intragenic marker 
for PRKAR1A were identifi ed in heterozygous state in 
the laser-captured microdissected cells using two diffe-
rent molecular approaches: automated sequencing and 
Genescan analysis, respectively. In summary, we de-
monstrated that the laser-captured PPNAD cells can 
preserve the WT PRKAR1A allele, indicating that this 
allele retention is not a consequence of contamination 
with normal surrounding cortex.
PRKAR1A haploinsuffi ciency has been hypothesi-
zed to cause tumours in patients with Carney complex 
(4). The most likely mechanism by which a truncated 
R1α protein could lead to cAMP signalling alterations is 
a dominant negative effect on R1α-mediated inhibition 
of the PKA catalytic subunit (12). The heterozygous 
p. Y21X mutation encodes a substitution of a highly 
conserved tyrosine by a stop codon, predicted to lead to 
a truncated protein in this young Brazilian male patient 
with PPNAD. Most of the PRKAR1A defects described 
to date are functionally null heterozygous mutations 
(5,12,19). Interestingly, two large families that share the 
578delTG PRKAR1A mutation have different pheno-
types, suggesting failure of PRKAR1A genotype-phe-
notype correlation (4,20). Similarly, a variable clinical 
expression ranging from subclinical to overt Cushing 
syndrome was associated with the p. Y21X mutation of 
Figure 2. (A) A transverse section of the adrenal gland indicates a PPNAD nodular area (circle), in which laser-captured micro-
dissection was performed. (B) A magnifi cation of the circle area (A) stained with Toluidine blue showing the microdissected 
areas (dashed outlines). (C and D) The dinucleotide repeat (CA)n intragenic marker for PRKAR1A gene was in heterozygous 
state as well as p. Y21X mutation in blood tissue and microdissected nodules, demonstrating that no PRKAR1A LOH was identi-
fi ed in laser-captured PPNAD cells.
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PRKAR1A in the family described here. This phenotypic 
variability is likely to be a consequence of as-yet-uniden-
tifi ed modifying genetic and/or environmental factors. 
Recently, Horvath and cols. (8) identifi ed germline 
mutations of the phosphodiesterase gene in 3 kindreds 
with Cushing syndrome and micronodular hyperplasia 
that were not caused by known defects in other genes. 
The fi nding of inactivating mutations of the phospho-
diesterase gene in micronodular hyperplasia raises the 
possibility of yet-unknown abnormalities in signal 
transduction proteins that interact with R1α and 
cAMP-dependent PKA, and eventually contribute to 
tumorigenesis in patients whose tumours do not dis-
play PRKAR1A LOH.
Similarities and dissimilarities between human Car-
ney complex phenotypes and murine Prkar1a haploin-
suffi ciency have been observed (19,21). Two hallmarks 
of Carney complex, spotty pigmentation and cardiac 
myxomas are not evident in Prkar1a+/- mice. Absence of 
cardiac myxomas in prkar1a+/- mice suggests that Prka-
r1a haploinsuffi ciency is insuffi cient to produce cardiac 
tumorigenesis. Nevertheless, tumours such as heman-
giosarcomas and myxoid fi brosarcomas that arise in 
Prkar1a+/- mice do not display prkar1a LOH (19). As 
demonstrated in a mouse model for the Carney complex 
tumour syndrome, we showed that human tumour cells 
can similarly preserve the WT PRKAR1A allele in affec-
ted tissues of patients with Carney complex.
In conclusion, we identifi ed a new PRKAR1A 
nonsense mutation (p. Y21X) associated with a variable 
clinical expression of the PPNAD phenotype. In addi-
tion, we demonstrated absence of PRKAR1A LOH in 
laser-captured tumour cells, indicating that adrenocor-
tical tumorigenesis in Carney complex occurs apart 
from the second hit.
Acknowledgments. We thank the staff of Laboratório de Hor-
mônios e Genética Molecular/LIM 42 for precise technical as-
sistance and Ms. Sonia Strong for the English review. Disclosure 
Statement: We declare no duality of fi nancial interest or direct or 
indirect confl ict of interest on the part of any author of this ma-
nuscript.
REFERENCES
1. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular 
features of the Carney complex: diagnostic criteria and recom-
mendations for patient evaluation. J Clin Endocrinol Metab. 
2001;86:4041-6.
2. Horvath A, Stratakis C. Primary pigmented nodular adrenocor-
tical disease and Cushing’s syndrome. Arq Bras Endocrinol 
Metabol. 2007;51:1238-44.
3. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, 
Cho YS, et al. Mutations of the gene encoding the protein kina-
se A type I-alpha regulatory subunit in patients with the Car-
ney complex. Nat Genet. 2000;26:89-92.
4. Casey M, Vaughan CJ, He J, Hatcher CJ, Winter JM, Weremo-
wicz S, et al. Mutations in the protein kinase A R1alpha regula-
tory subunit cause familial cardiac myxomas and Carney 
complex. J Clin Invest. 2000;106:R31-8.
5. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis 
CA. Genetic heterogeneity and spectrum of mutations of the 
PRKAR1A gene in patients with the carney complex. Hum Mol 
Genet. 2000;9:3037-46.
6. Sandrini F, Stratakis C. Clinical and molecular genetics of pri-
mary pigmented nodular adrenocortical disease. Arq Bras En-
docrinol Metabol. 2004;48:637-41.
7. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kast-
ner DL, et al. Carney complex, a familial multiple neoplasia and 
lentiginosis syndrome. Analysis of 11 kindreds and linkage to 
the short arm of chromosome 2. J Clin Invest. 1996;97:699-705.
8. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin 
L, Griffi n KJ, et al. A genome-wide scan identifi es mutations in 
the gene encoding phosphodiesterase 11A4 (PDE11A) in indi-
viduals with adrenocortical hyperplasia. Nat Genet. 
2006;38:794-800.
9. Tsilou ET, Chan CC, Sandrini F, Rubin BI, Shen de F, Carney JA, 
et al. Eyelid myxoma in Carney complex without PRKAR1A 
allelic loss. Am J Med Genet A. 2004;130:395-7.
10. Bossis I, Voutetakis A, Matyakhina L, Pack S, Abu-Asab M, 
Bourdeau I, et al. A pleiomorphic GH pituitary adenoma from 
a Carney complex patient displays universal allelic loss at the 
protein kinase A regulatory subunit 1A (PRKARIA) locus. J 
Med Genet. 2004;41:596-600.
11. Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton 
JP, et al. Mutations of the PRKAR1A gene in Cushing’s syndro-
me due to sporadic primary pigmented nodular adrenocorti-
cal disease. J Clin Endocrinol Metab. 2002;87:4324-9.
12. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, 
Jullian E, Delemer B, et al. Molecular analysis of the cyclic 
AMP-dependent protein kinase A (PKA) regulatory subunit 1A 
(PRKAR1A) gene in patients with Carney complex and primary 
pigmented nodular adrenocortical disease (PPNAD) reveals 
novel mutations and clues for pathophysiology: augmented 
PKA signaling is associated with adrenal tumorigenesis in PP-
NAD. Am J Hum Genet. 2002;71:1433-42.
13. Parhar IS, Ogawa S, Sakuma Y. Laser-captured single digoxige-
nin-labeled neurons of gonadotropin-releasing hormone types 
reveal a novel G protein-coupled receptor (Gpr54) during matu-
ration in cichlid fi sh. Endocrinology. 2004;145:3613-8.
14. Francis DP, Willson K, Davies LC, Coats AJ, Piepoli M. Quantita-
tive general theory for periodic breathing in chronic heart failu-
re and its clinical implications. Circulation. 2000;102:2214-21.
15. Mavrakis M, Lippincott-Schwartz J, Stratakis CA, Bossis I. De-
pletion of type IA regulatory subunit (RIalpha) of protein ki-
nase A (PKA) in mammalian cells and tissues activates mTOR 
and causes autophagic defi ciency. Hum Mol Genet. 2006;15: 
2962-71.
16. Shattuck TM, Costa J, Bernstein M, Jensen RT, Chung DC, Ar-
nold A. Mutational analysis of Smad3, a candidate tumor sup-
pressor implicated in TGF-beta and menin pathways, in 
Arq Bras Endocrinol Metab 2008;52/8 1263
Absence of PRKAR1A LOH in microdissected PPNAD tissue
Almeida et al.
c
o
p
yr
ig
h
t©
 A
BE
&
M
 t
o
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s
parathyroid adenomas and enteropancreatic endocrine tu-
mors. J Clin Endocrinol Metab. 2002;87:3911-4.
17. Pinto EM, Billerbeck AE, Fragoso MC, Mendonca BB, Latronico 
AC. Deletion mapping of chromosome 17 in benign and ma-
lignant adrenocortical tumors associated with the Arg337His 
mutation of the p53 tumor suppressor protein. J Clin Endocri-
nol Metab. 2005;90:2976-81.
18. Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, 
Del Viscovo L, et al. Subclinical Cushing’s syndrome in pa-
tients with adrenal incidentaloma: clinical and biochemical 
features. J Clin Endocrinol Metab. 2000;85:1440-8.
19. Veugelers M, Wilkes D, Burton K, McDermott DA, Song Y, 
Goldstein MM, et al. Comparative PRKAR1A genotype-pheno-
type analyses in humans with Carney complex and prkar1a 
haploinsuffi cient mice. Proc Natl Acad Sci USA. 2004;101: 
14222-7.
20. Danoff A, Jormark S, Lorber D, Fleischer N. Adrenocortical mi-
cronodular dysplasia, cardiac myxomas, lentigines, and spin-
dle cell tumors. Report of a kindred. Arch Intern Med. 
1987;147:443-8.
21. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH, 2nd, Carney 
JA, Westphal H, et al. A mouse model for the Carney complex tu-
mor syndrome develops neoplasia in cyclic AMP-responsive 
tissues. Cancer Res. 2005;65:4506-14.
Correspondence to: 
Maria Candida Barisson Villares Fragoso
Unidade de Endocrinologia do Desenvolvimento e 
Laboratório de Hormônios e Genética Molecular LIM-42, 
Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo
Av. Dr. Enéas de Carvalho Aguiar, 155, 20 andar Bloco 6
05403-900, São Paulo, SP, Brasil
E-mail: mariafragoso@uol.com.br
